PMID- 7530889
OWN - NLM
STAT- MEDLINE
DCOM- 19950228
LR  - 20190814
IS  - 0001-6314 (Print)
IS  - 0001-6314 (Linking)
VI  - 90
IP  - 4
DP  - 1994 Oct
TI  - Intrathecal synthesis of anti-myelin basic protein IgG in HIV-1+ patients.
PG  - 285-92
AB  - Human immunodeficiency virus type 1 (HIV-1)-infected individuals frequently 
      develop a broad spectrum of neurological syndromes, classified as 
      HIV-1-associated cognitive/motor complex. Diffuse demyelination of hemispheric 
      white matter is a commonly observed in HIV-1 infected brain, but the events 
      leading to myelin destruction are still obscure. Since oligodendrocyte infection 
      by HIV-1 is not proven as yet, myelin damage in HIV-1 infection may result from 
      indirect mechanisms such as the excessive release of myelinotoxic substances or 
      the triggering of autoimmune responses directed to myelin constituents. To verify 
      the latter hypothesis, we searched for elevated anti-myelin basic protein (MBP) 
      IgG levels in the cerebrospinal fluid (CSF) and serum of 25 patients with HIV-1 
      infection, 12 with multiple sclerosis (MS), and 9 with non-inflammatory 
      neurological diseases (NIND). CSF, but not serum, anti-MBP IgG levels were more 
      frequently elevated in HIV-1+ (16/25, 64%) than in MS (3/12, 25%) or NIND (0/9) 
      patients. By using the anti-MBP IgG index, the anti-MBP IgG antibody specificity 
      index (ASI), and the search for anti-MBP oligoclonal IgG, we ascertained that 
      anti-MBP IgG were produced within the CNS in 13 of 25 (52%) HIV-1+, in 6 of 12 
      (50%) MS, and in none of NIND patients. The incidence of increased CSF anti-MBP 
      IgG levels was higher among HIV-1+ patients at stage II-III (4/4, 100%) or at 
      stage IV B (7/9, 78%) than among those at stage IV C-IV D (5/12, 42%). Although 
      our data indicate that intrathecal anti-MBP IgG may occur early during HIV-1 
      infection and that they are more common in patients with HIV-1-associated 
      cognitive/motor complex, the possible demyelinating role of these antibodies 
      remains to be demonstrated.
FAU - Maimone, D
AU  - Maimone D
AD  - Institute of Neurological Sciences, University of Siena, Italy.
FAU - Annunziata, P
AU  - Annunziata P
FAU - Cioni, C
AU  - Cioni C
FAU - Leonardi, A
AU  - Leonardi A
FAU - Guazzi, G C
AU  - Guazzi GC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins)
RN  - 0 (Myelin Basic Protein)
RN  - 0 (Oligoclonal Bands)
SB  - IM
MH  - AIDS Dementia Complex/diagnosis/*immunology
MH  - Autoantibodies/*cerebrospinal fluid
MH  - Blood-Brain Barrier/immunology
MH  - Diagnosis, Differential
MH  - Enzyme-Linked Immunosorbent Assay
MH  - HIV Seropositivity/diagnosis/*immunology
MH  - HIV-1/*immunology
MH  - Humans
MH  - Immunoglobulin G/*cerebrospinal fluid
MH  - Immunoglobulins/cerebrospinal fluid
MH  - Multiple Sclerosis/diagnosis/immunology
MH  - Myelin Basic Protein/*immunology
MH  - Myelin Sheath/immunology
MH  - Nervous System Diseases/diagnosis/immunology
MH  - Neurologic Examination
MH  - Neuropsychological Tests
MH  - Oligoclonal Bands
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1111/j.1600-0404.1994.tb02723.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 1994 Oct;90(4):285-92. doi: 
      10.1111/j.1600-0404.1994.tb02723.x.